不同治疗方案在AML患者中的疗效比较

The comparison of efficacy of different therapeutic strategies in adult acute myeloid leukemia patients

目的 :探析成人初治急性髓系白血病(AML)治疗中柔红霉素+阿糖胞苷诱导化疗(DA方案)与阿糖胞苷+去甲氧柔红霉素(IA方案)的临床价值。方法 :分析2013年3月~2016年4月在我院接受治疗的72例成人初治AML患者的临床资料。根据诱导化疗方案的不同可以将入选者分成DA组(34例)和IA组(38例)两组。比较两组患者的基线资料、治疗效果、安全性以及生存状况。结果 :两组患者的基线资料无显著差异。IA组1、2个疗程后的总有效率均明显高于DA组。两组患者化疗后均出现感染、恶心呕吐以及骨髓抑制等副反应,且均可耐受。DA组患者的CR复发率(61.3%)比IA组(83.3%)高,差异无统计学意义;中位生存时间(1.8年)比DA组(1.2年)长。结论 :与DA方案相比,IA方案治疗初治成人AML的疗效更为突出,临床上值得进一步推广和应用。

Objective Our retrospective study was aimed toanalyze the clinical value of cytarabine+ daunorubicin(DA scheme)and cytarabine+ darubicin(IA scheme)in treating the adult acute myeloid leukemia(AML)patients. Methods Clinical data of 72 adult patients with AMLreceived treatment at our hospitalfrom March, 2013 to April, 2016 was retrospectivelyanalyzed. Patients included were divided into two groups according to the treatment, DA group(34 cases)and IA group(38 cases). The general information, therapeutic efficacy, safety and survival of patients in two groups were compared. Results The general information in two groups had no statistical difference. The complete remission rate after 1, 2 course of treatment in IA group were obviously higher than those in DA group. The side effects of patients in two groups after chemotherapy included bone marrow suppression, infection nausea and vomiting, which the patient could tolerate. The recurrence of CR in DA group(61.3%)was higher than that(83.3%)in IA group. The survival time in IA group(1.8 years)was longer than that(1.2 years)in DA group. Conclusion Comparing to the DA scheme, the IA scheme has better curative effect in treating the adult patients with AML. It's worth promoting.